ProCE Banner Activity

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the United States

Podcast Episodes
In this episode, listen to Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States.

Released: February 01, 2021

Expiration: January 31, 2022

No longer available for credit.

Share

Faculty

Petros Grivas

Petros Grivas, MD, PhD

Associate Professor
Clinical Director
, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Jonathan Rosenberg

Jonathan Rosenberg, MD

Attending Physician, Chief
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Supporters

Supported by an educational grant from

Pfizer and EMD Serono

Faculty Disclosure

Primary Author

Petros Grivas, MD, PhD

Associate Professor
Clinical Director
, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Petros Grivas, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Dyania, EMD Serono, Genentech/Roche, Immunomedics, Janssen, Merck, Mirati, Pfizer, and Seattle Genetics and funds for research support from Bavarian Nordic, Bristol-Myers Squibb, Clovis Oncology, Debiopharm, GlaxoSmithKline, Immunomedics, Kure It Cancer Research, Merck, Pfizer, and QED Therapeutics.

Jonathan Rosenberg, MD

Attending Physician, Chief
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Jonathan E. Rosenberg, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Lilly, Merck, Roche/Genentech, and Seattle Genetics and funds for research support from AstraZeneca, Bayer, Merck, Roche/Genentech, and Seattle Genetics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.